ReviewBiomarker research2016
CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia.
Review in Biomarker research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- Expression of Oct3/4 isoforms and its association with the risk of relapse in acute lymphoblastic leukemia.Biomedical reports · 2025Article
- Cross-Sectional Study: Associations of A20 and Cezanne with Leukocyte Accumulation in B-Cell Acute Lymphoblastic Leukemia.Medicina (Kaunas, Lithuania) · 2025Article
- CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activity.PloS one · 2025Article
- Article
- Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches.International journal of molecular sciences · 2024Review
- Signaling pathways governing the behaviors of leukemia stem cells.Genes & diseases · 2024Review
- Zebrafish drug screening identifies Erlotinib as an inhibitor of Wnt/β-catenin signaling and self-renewal in T-cell acute lymphoblastic leukemia.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- The shape of cancer relapse: Topological data analysis predicts recurrence in paediatric acute lymphoblastic leukaemia.PLoS computational biology · 2023Article
- The Role of Inflammation in Age-Associated Changes in Red Blood System.International journal of molecular sciences · 2023Article
- FAT1 Gene Expression in Iranian Acute Lymphoid and Myeloid Leukemia Patients.International journal of hematology-oncology and stem cell research · 2023Article
- Can CD34Frontiers in pediatrics · 2023Review
- Editorial: Pediatric acute lymphoblastic leukemia: what's next?Frontiers in pediatrics · 2023Article
- Immunophenotypic characterization of acute leukemias in Bahia, Brazil.Einstein (Sao Paulo, Brazil) · 2023Article
- The Impact of Exosomes/Microvesicles Derived from Myeloid Dendritic Cells Cultured in the Presence of Calcitriol and Tacalcitol on Acute B-Cell Precursor Cell Lines withJournal of clinical medicine · 2022Article
- Cell surface expression of GRP78 and CXCR4 is associated with childhood high-risk acute lymphoblastic leukemia at diagnostics.Scientific reports · 2022Article
- Article
- Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance.Clinical epigenetics · 2021Review
- Article
- Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD34 and CD38 proteins are usually used as surface markers to identify HSCs and Leukemic stem cells. However, there have been cases that lacked CD34 or CD38 protein but still had leukemia initiating capacity in B-ALL suggesting the restrictive of these two markers. CD34 and CD38 expression were detected in most B-ALL and can serve as a specific biomarker for the prognosis of this subset of leukemia. Lack of CD34 or high CD38 expression is associated with favorable prognosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.